Trial Profile
Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion From an Erythropoiesis Stimulating Agent (ESA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASPEN
- Sponsors FibroGen
- 14 Dec 2021 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 Planned End Date changed from 1 Aug 2021 to 28 Aug 2021.
- 20 Apr 2021 Planned primary completion date changed from 1 Feb 2021 to 31 Jul 2021.